Display options
Cite
Seckinger A, Hillengass J, Emde M, et al. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Front Immunol. 2018;9:1676doi: 10.3389/fimmu.2018.01676.
Seckinger, A., Hillengass, J., Emde, M., Beck, S., Kimmich, C., Dittrich, T., Hundemer, M., Jauch, A., Hegenbart, U., Raab, M. S., Ho, A. D., Schönland, S., & Hose, D. (2018). CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Frontiers in immunology, 91676. https://doi.org/10.3389/fimmu.2018.01676
Seckinger, Anja, et al. "CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance." Frontiers in immunology vol. 9 (2018): 1676. doi: https://doi.org/10.3389/fimmu.2018.01676
Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018. PMID: 30079070; PMCID: PMC6062598.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Frontiers in immunology

Anja Seckinger, Jens Hillengass, Martina Emde, Susanne Beck, Christoph Kimmich, Tobias Dittrich, Michael Hundemer, Anna Jauch, Ute Hegenbart, Marc-Steffen Raab, Anthony D Ho, Stefan Schönland, Dirk Hose

Affiliations

  1. Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
  2. Institut für Humangenetik, Universität Heidelberg, Heidelberg, Germany.

PMID: 30079070 PMCID: PMC6062598 DOI: 10.3389/fimmu.2018.01676

Abstract

Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortezomib plus dexamethasone, and tolerable side effects. Despite clinical use, many questions remain. In this manuscript, we address three of these: first, upfront CD38 target-expression in AL-amyloidosis, monoclonal gammopathy of unknown significance (MGUS), asymptomatic, symptomatic, and relapsed multiple myeloma. Second, relation of CD38-expression to survival, disease stages, molecular entities, and high-risk definitions. Third, alternative splicing or lack of CD38-expression as potential mechanisms of upfront resistance. We assessed CD138-purified plasma cell samples from 196 AL-amyloidosis, 62 MGUS, 259 asymptomatic, 764 symptomatic, and 90 relapsed myeloma patients, including longitudinal pairs of asymptomatic/symptomatic (

Keywords: CD38; alternative splicing; amyloidosis; immunotherapy; multiple myeloma; survival

References

  1. Leukemia. 2012 Nov;26(11):2406-13 - PubMed
  2. Bioinformatics. 2015 Jan 15;31(2):166-9 - PubMed
  3. Haematologica. 2011 Jan;96(1):87-95 - PubMed
  4. Blood. 2009 Apr 30;113(18):4331-40 - PubMed
  5. J Clin Oncol. 2005 May 20;23(15):3412-20 - PubMed
  6. Nucleic Acids Res. 2016 Jan 4;44(D1):D574-80 - PubMed
  7. Bioinformatics. 2010 Jan 1;26(1):139-40 - PubMed
  8. BMC Bioinformatics. 2011 Aug 04;12:323 - PubMed
  9. J Clin Oncol. 2011 May 10;29(14):1924-33 - PubMed
  10. Blood. 2007 Oct 1;110(7):2586-92 - PubMed
  11. Blood. 2016 Jul 28;128(4):594-602 - PubMed
  12. Am J Clin Pathol. 2004 Apr;121(4):482-8 - PubMed
  13. Cytometry B Clin Cytom. 2017 Mar;92(2):145-152 - PubMed
  14. Methods Mol Biol. 2018;1792:97-115 - PubMed
  15. J Clin Oncol. 2013 Dec 1;31(34):4325-32 - PubMed
  16. Bioinformatics. 2013 Jan 1;29(1):15-21 - PubMed
  17. Cancer Cell. 2017 Mar 13;31(3):396-410 - PubMed
  18. Blood. 2007 Apr 15;109(8):3489-95 - PubMed
  19. Blood. 2007 Mar 15;109(6):2276-84 - PubMed
  20. Blood. 2016 Aug 18;128(7):959-70 - PubMed
  21. Genome Biol. 2004;5(10):R80 - PubMed
  22. Blood. 2005 Aug 1;106(3):1021-30 - PubMed
  23. Clin Cancer Res. 2015 Jun 15;21(12):2802-10 - PubMed
  24. Blood. 2005 Jul 1;106(1):296-303 - PubMed
  25. N Engl J Med. 2015 Sep 24;373(13):1207-19 - PubMed
  26. Blood. 2008 Jan 15;111(2):785-9 - PubMed
  27. Biostatistics. 2007 Jan;8(1):118-27 - PubMed
  28. Blood. 2015 Dec 17;126(25):2713-9 - PubMed
  29. J Clin Oncol. 2015 Apr 20;33(12):1371-8 - PubMed
  30. Blood. 2017 Aug 17;130(7):900-902 - PubMed
  31. Oncotarget. 2016 Aug 11;8(49):84847-84862 - PubMed
  32. N Engl J Med. 2016 Aug 25;375(8):754-66 - PubMed
  33. N Engl J Med. 2007 Jun 21;356(25):2582-90 - PubMed
  34. Cancer. 1975 Sep;36(3):842-54 - PubMed
  35. Bioinformatics. 2013 May 1;29(9):1149-57 - PubMed
  36. Blood. 2012 Jan 26;119(4):940-8 - PubMed
  37. Leukemia. 2015 Oct;29(10):2039-49 - PubMed
  38. Leukemia. 2013 Apr;27(4):941-6 - PubMed
  39. J Clin Oncol. 2004 Sep 15;22(18):3751-7 - PubMed
  40. N Engl J Med. 2016 Oct 6;375(14):1319-1331 - PubMed
  41. Blood. 2010 Aug 26;116(8):1220-7 - PubMed
  42. Blood. 2012 Aug 2;120(5):1087-94 - PubMed
  43. Blood. 2017 Jun 22;129(25):3386-3388 - PubMed
  44. N Engl J Med. 2018 Feb 8;378(6):518-528 - PubMed
  45. Front Immunol. 2014 Mar 31;5:137 - PubMed
  46. Blood. 2006 Apr 1;107(7):2633-8 - PubMed

Publication Types